Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer April 28, 2026
FDA Accepts for Priority Review Supplemental BLA for Ziihera® (zanidatamab-hrii) Combo in 1L HER2+ Locally Advanced or Metastatic GEA April 28, 2026
Dose expansion in clinical study of spevatamig + chemo for treatment of biliary tract cancer April 28, 2026
First Pancreatic Cancer Patient in Europe treated with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial April 28, 2026
Updated interim data from Ph 1/2 study of ozekibart (INBRX-109) + FOLFIRI in patients with metastatic CRC announced April 28, 2026
Type C meeting with FDA provides alignment on design of a pivotal clinical study to support approval of pelareorep in patients with unresectable metastatic SCAC April 28, 2026
FDA Fast Track Designation for BBO-11818 for Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma April 28, 2026
Daraxonrasib Demonstrates Unprecedented OS Benefit in Ph 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer April 21, 2026
Supplemental BLA submitted to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma; Included in updated NCCN Guidelines April 21, 2026
Nature Medicine Publishes Results Showing Doubling of the Rate of Survival with Elraglusib + Chemo in 1L Metastatic Pancreatic Ductal Adenocarcinoma April 21, 2026
Positive PDS01ADC Interim Ph 2 Trial Data from Stage 1 of NCI-led Metastatic CRC Trial Published April 21, 2026
Ph 2 trial of botensilimab (BOT), balstilimab (BAL) & agenT-797 in GEJ cancer shows 77% DCR and long-term survival beyond 20 months in heavily pretreated patients April 21, 2026
Adagene and Incyte to Evaluate Muzastotug (ADG126) in Combination with INCA33890 in Patients with MSS CRC April 15, 2026
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 15, 2026
Recruitment in AMPLICITY trial halted after three Dose Limiting Toxicities (DLTs) related to mFOLFIRINOX April 15, 2026
Updated Data from Ph 1b/2 Study of Muzastotug + KEYTRUDA in Late-line Patients with MSS CRC Demonstrate Improved Durability of Response April 15, 2026
First Patient Dosed in Ph 3 RASolute 303 Trial of Daraxonrasib in 1L Metastatic Pancreatic Cancer April 7, 2026
Imfinzi + Imjudo combined with lenvatinib and TACE demonstrated a statistically significant PFS improvement in embolisation-eligible unresectable liver cancer in EMERALD-3 Ph 3 trial April 7, 2026
Type C FDA Meeting Announced to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer April 7, 2026
FDA Accepts Priority Review of NDA for Lirafugratinib as 2L Cholangiocarcinoma Treatment April 7, 2026
